monarchE Archives - Medical Conferences

Benefit of abemaciclib plus fulvestrant after progression on a CDK4/6 inhibitor

Presented By

Prof. Kevin Kalinsky, Emory School of Medicine, GA, USA

Trial

postMONARCH

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:02

ctDNA is prognostic of worse outcomes for CDK4/6 therapy

Presented By

Prof. Sherene Loi, Peter MacCallum Cancer Centre, Australia

Trial

Phase 3, monarchE

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:56

monarchE: No predictive biomarkers revealed with molecular profiling

Presented By

Prof. Nick Turner, The Royal Marsden Hospital and Institute of Cancer Research, UK

Trial

Phase 3, monarchE

Conference

SABCS 2023

Type

News article

11 January 2024 14:58

Benefit of adjuvant abemaciclib continues to deepen at longer follow-up

Presented By

Prof. Stephen Johnston, The Royal Marsden NHS Foundation Trust, UK

Trial

Phase 3, monarchE

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:10

SABCS 2020: Updated monarchE trial shows abemaciclib continues to benefit patients with high-risk, HR-positive, HER2-negative, early-stage breast cancer

Presented By

Dr Priya Rastogi, University of Pittsburgh, Pennsylvania

Trial

monarchE, PALLAS, Penelope-B

Journal

Physician's Weekly

Conference

SABCS 2020

15 April 2021 16:14

CDK4/6 inhibition in high-risk early breast cancer

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 16:20